Kobayashi Pharmaceutical Co Ltd 2024 Integrated Report
Company: Kobayashi Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2024
Type: Integrated Report
Pages: 92
The report describes Kobayashi Pharmaceutical's response to the red yeast rice-related product issue, including strengthened quality and safety systems, a function-based organization, and major Board and governance reforms. It reports 2024 Group environmental performance, including 8 in Scope 1, 19 in Scope 2, 488 in Scope 3, and 229 t of waste generated in the Group highlights. The company also reports SBTi-certified targets to reduce Scope 1 and 2 emissions by 51% and Scope 3 emissions by 15% by 2030 from a 2018 base. Sustainability oversight is organized through a Sustainability Committee established directly under the Board of Directors.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.